Tag: Herpes Zoster (Shingles)
Herpes Zoster Recombinant Vaccine Seems Most Effective
However, adjuvant recombinant subunit vaccine tied to more injection site adverse events
Robust Immune Responses for Herpes Zoster Subunit Vaccine
Humoral response seen for 97.8 percent of HZ/su vaccine recipients versus 2 percent of placebo
Adjuvanted Shingles Subunit Vaccine Likely More Cost-Effective
Less overall cost and more effective than live attenuated vaccine at all ages; generally a good value
Herpes Zoster May Increase Risk of Myocardial Infarction, Stroke
More research is needed, but doctors should warn patients, researcher says
2006 to 2013 Saw Increase in ER Use for Herpes Zoster
Increase in number of emergency department visits and costs for HZ-related ER visits
Zoster Ups Stroke Risk in Patients With Autoimmune Disease
For patients with autoimmune disease, herpes zoster tied to increased stroke risk in first 90 days
CDC Finds Vaccination Coverage Varies for Adults With Diabetes
Influenza vaccination coverage more prevalent than pneumococcal or hepatitis B vaccination
Experimental Zoster Vaccine Effective in Adults Aged 70+
Found to protect 89.8 percent of adults age 70 and up
Pain and Itch Highly Prevalent Months After Herpes Zoster
Pain linked to increased costs and has large impact on quality of life; itch has limited impact on QoL
Stellate Ganglion Block Beneficial in Postherpetic Neuralgia
Report demonstrates benefit in severe photophobia secondary to trigeminal postherpetic neuralgia
